Objective <p>To explore the association between Vaccination Status and Clinical Characteristics Among Young Adults Infected With COVID-19.</p> Methods <p>We conducted a cross-sectional Survey among young adults aged 16–35 years in Tianjin, China. Our analysis focused on COVID-19 infection rates, risk factors, demographic characteristics, and clinical symptoms.</p> Results <p>We collected 738 valid questionnaires between December 20 to 23, 2022, achieving a response rate of 98.27%. Among the 412 infected participants, 33.25% were male and 66.75% were female, with a marginal significant difference (<i>P</i> = 0.054). The distribution of infected participants across various age groups, as well as the presence or absence of co-residents, showed a significant difference between the infected and uninfected cohorts (<i>P</i> = 0.003 and <i>P</i> &lt; 0.001, respectively). Compared with participants who received two or less vaccine dose, participants who had received three or more doses of vaccine had a significantly lower incidence of headache (0–2 vs. &gt; = 3 doses: 80.43% and 69.38%, <i>P</i> = 0.038), olfactory reduction or loss (0–2 vs. &gt; = 3 doses: 22.83% and 14.06%, <i>P</i> = 0.043). Compared with the time since vaccination of 7–12 months, those vaccinated with less than 6 months or more than 12 months exhibited a higher incidence of fatigue (&lt; 6 vs. 7–12 vs. &gt; 12 months: 75.41%, 63.13% and 77.61%, <i>P</i> = 0.009) but a lower incidence of vomiting (&lt; 6 vs. 7–12 vs. &gt; 12 months: 8.20%, 17.51% and 8.21%, <i>P</i> = 0.020).</p> Conclusion <p>Our study found that young adults who received three or more doses of the COVID-19 vaccine had a lower incidence of symptoms such as headache and olfactory reduction. These findings underscore the importance of vaccination in mitigating the severity of COVID-19 symptoms and provide valuable insights for future public health strategies and vaccine policies.</p>